A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer-Reference-Cited by-同舟云学术

A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer

Published:2021-03-01 Issue:1 Volume:7 Page:8-19
ISSN:2475-3246
Container-title:Journal of Pancreatic Cancer
language:en
Short-container-title:Journal of Pancreatic Cancer

Author:

Muscarella Peter¹,Bekaii-Saab Tanios²,McIntyre Kristi³,Rosemurgy Alexander⁴,Ross Sharona B.⁴,Richards Donald A.⁵,Fisher William E.⁶,Flynn Patrick J.⁷,Mattson Alicia⁸,Coeshott Claire⁸,Roder Heinrich⁹,Roder Joanna⁹,Harrell Frank E.¹⁰,Cohn Allen¹¹,Rodell Timothy C.⁸,Apelian David⁸,

Affiliation:

1. Department of Surgery, Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.

2. Mayo Clinic Cancer Center, Phoenix, Arizona, USA.

3. Texas Oncology, US Oncology Research, Dallas, Texas, USA.

4. Digestive Disorders Institute, AdventHealth Tampa, Tampa, Florida, USA.

5. Texas Oncology, US Oncology Research, Tyler, Texas, USA.

6. Baylor College of Medicine, Houston, Texas, USA.

7. Minnesota Oncology, US Oncology Research, Minneapolis, Minnesota, USA.

8. Smuggler Mountain Group (SMG, Inc.), Aspen, Colorado, USA.

9. Biodesix, Inc., Boulder, Colorado, USA.

10. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

11. Rocky Mountain Cancer Center, Denver, Colorado, USA.